Free Trial
NASDAQ:AMBI

AMBI (AMBI) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$4.09
$4.47
50-Day Range
N/A
52-Week Range
N/A
Volume
4,781 shs
Average Volume
28,052 shs
Market Capitalization
$237.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
AMBI stock logo

About AMBI Stock (NASDAQ:AMBI)

Ambit Biosciences Corporation is a biopharmaceutical company. The Company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. The Company’s lead drug candidate, quizartinib, is in Phase IIb clinical development in patients with relapsed/refractory acute myeloid leukemia (AML). The Company’s second drug candidate in clinical development, AC410, is a potent, selective, orally-administered, small molecule inhibitor of Janus kinase 2 (JAK2) that has potential utility for the treatment of autoimmune and inflammatory diseases. The Company’s third program consists of two selective small molecule compounds, AC708 and AC855, which inhibit the colony-stimulating factor-1 receptor (CSF1R), a receptor tyrosine kinase.

AMBI Stock News Headlines

Aashu makes directorial and lead debut in 'Tommy'
What we lose when words lose meaning
Pre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳
45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A investment now open.
Secret Whole Body Deodorant Helps You Smell Great Even in the Afterlife
Two men charged with fentanyl death
Pre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳
45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A investment now open.
KuBe Gets New Director
See More Headlines
Receive AMBI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AMBI and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/09/2024
Today
9/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Sanitary services
Sub-Industry
N/A
Current Symbol
NASDAQ:AMBI
Fax
N/A
Employees
7,000
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$518.81 million
Cash Flow
$0.73 per share
Book Value
$5.79 per share

Miscellaneous

Free Float
46,561,000
Market Cap
$237.79 million
Optionable
Not Optionable
Beta
0.64
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

AMBI Stock Analysis - Frequently Asked Questions

How were AMBI's earnings last quarter?

AMBI (NASDAQ:AMBI) announced its quarterly earnings data on Friday, August, 9th. The biopharmaceutical company reported $0.24 earnings per share (EPS) for the quarter. The biopharmaceutical company earned $142.09 million during the quarter.

What other stocks do shareholders of AMBI own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AMBI investors own include Alexion Pharmaceuticals (ALXN), Amarin (AMRN), Broadcom (BRCM), Cytokinetics (CYTK), Delta Air Lines (DAL), Fortress Biotech (FBIO) and FireEye (FEYE).

This page (NASDAQ:AMBI) was last updated on 9/7/2024 by MarketBeat.com Staff

From Our Partners